BACKGROUND AND OBJECTIVES: Vitamin D has gained attention for its pleiotropic effects in areas other than bone metabolism, and the effects of vitamin D in preventing respiratory infections have been reported as one of its immunomodulating properties. This study assessed the preventive effect of vitamin D receptor activator (VDRA) on respiratory infections in dialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Maintained Japanese hemodialysis patients (n = 508) were observed for 5 years, and the incidence of hospitalization during this period because of acute respiratory infection (ARI) was recorded. RESULTS: Of the 508 patients, 212 had taken oral VDRA at the start of the study, whereas 296 patients had not received it. During the 5-year follow-up period, 57 patients were hospitalized because of ARIs. Kaplan-Meier analysis revealed that the incidence of hospitalization because of respiratory infection was significantly lower in patients who had been treated with VDRA compared with patients who had not (log rank test; P = 0.02). The multivariate Cox proportional hazards model demonstrated that the patients who had taken oral VDRA were at a significantly lower risk of hospitalization because of respiratory disease (hazard ratio 0.47, 95% confidence interval 0.25 to 0.90). CONCLUSIONS: The findings of this study suggest that the administration of oral VDRA has a preventive effect on the incidence of ARIs in dialysis patients.
BACKGROUND AND OBJECTIVES:Vitamin D has gained attention for its pleiotropic effects in areas other than bone metabolism, and the effects of vitamin D in preventing respiratory infections have been reported as one of its immunomodulating properties. This study assessed the preventive effect of vitamin D receptor activator (VDRA) on respiratory infections in dialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Maintained Japanese hemodialysis patients (n = 508) were observed for 5 years, and the incidence of hospitalization during this period because of acute respiratory infection (ARI) was recorded. RESULTS: Of the 508 patients, 212 had taken oral VDRA at the start of the study, whereas 296 patients had not received it. During the 5-year follow-up period, 57 patients were hospitalized because of ARIs. Kaplan-Meier analysis revealed that the incidence of hospitalization because of respiratory infection was significantly lower in patients who had been treated with VDRA compared with patients who had not (log rank test; P = 0.02). The multivariate Cox proportional hazards model demonstrated that the patients who had taken oral VDRA were at a significantly lower risk of hospitalization because of respiratory disease (hazard ratio 0.47, 95% confidence interval 0.25 to 0.90). CONCLUSIONS: The findings of this study suggest that the administration of oral VDRA has a preventive effect on the incidence of ARIs in dialysis patients.
Authors: K Makibayashi; M Tatematsu; M Hirata; N Fukushima; K Kusano; S Ohashi; H Abe; K Kuze; A Fukatsu; T Kita; T Doi Journal: Am J Pathol Date: 2001-05 Impact factor: 4.307
Authors: Wendy L St Peter; Shuling Li; Jiannong Liu; David T Gilbertson; Thomas J Arneson; Allan J Collins Journal: Pharmacotherapy Date: 2009-02 Impact factor: 4.705
Authors: Daniela Veit Barreto; Fellype Carvalho Barreto; Sophie Liabeuf; Mohammed Temmar; Francis Boitte; Gabriel Choukroun; Albert Fournier; Ziad A Massy Journal: Clin J Am Soc Nephrol Date: 2009-05-14 Impact factor: 8.237
Authors: Francesca Tentori; Justin M Albert; Eric W Young; Margaret J Blayney; Bruce M Robinson; Ronald L Pisoni; Takashi Akiba; Roger N Greenwood; Naoki Kimata; Nathan W Levin; Luis M Piera; Rajiv Saran; Robert A Wolfe; Friedrich K Port Journal: Nephrol Dial Transplant Date: 2008-11-21 Impact factor: 5.992